Oruka Therapeutics (ORKA) Share-based Compensation (2010 - 2026)
Oruka Therapeutics (ORKA) posted quarterly Share-based Compensation of $7.0 million for Q1 2026, up 42.7% year-over-year from $4.9 million in Q1 2025, and up 69.33% quarter-over-quarter from $4.1 million in Q4 2025.
Oruka Therapeutics (ORKA) Share-based Compensation (2010 - 2026) Analysis & Trends
Oruka Therapeutics' Share-based Compensation history runs 17 years deep, the most recent figure standing at $7.0 million for Q1 2026.
- In Q1 2026, Share-based Compensation rose 42.7% year-over-year to $7.0 million; the TTM figure through Mar 2026 stood at $26.3 million (down 7.64% YoY), while the FY2025 annual figure was $24.2 million, down 16.7% from the prior year.
- Share-based Compensation for Q1 2026 stood at $7.0 million, up from $4.1 million in the prior quarter.
- The five-year high for Share-based Compensation was $13.9 million in Q4 2024, with the low at $97000.0 in Q3 2022.
- The 5-year median for Share-based Compensation is $204000.0 (2023), against an average of $3.3 million.
- The sharpest annual moves came in 2022 and 2024: Share-based Compensation plunged 70.94% in 2022, then soared 9784.4% in 2024.
- Oruka Therapeutics' Share-based Compensation stood at $120000.0 in 2022, then grew by 17.5% to $141000.0 in 2023, then jumped by 9784.4% to $13.9 million in 2024, then plunged by 70.47% to $4.1 million in 2025, then jumped by 69.33% to $7.0 million in 2026.
- Business Quant data shows ORKA's Share-based Compensation at $7.0 million in Q1 2026, $4.1 million in Q4 2025, and $10.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Oruka Therapeutics | 6.98 Bn | 5.25 Bn | - | 88.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 88.50 Mn |
| Jun 30, 2026 | 88.50 Mn |
| Mar 31, 2026 | 6.97 Mn |
| Mar 31, 2026 | 6.97 Mn |
| Dec 31, 2025 | 4.12 Mn |
| Dec 31, 2025 | 4.12 Mn |
| Sep 30, 2025 | 10.17 Mn |
| Sep 30, 2025 | 10.17 Mn |
| Jun 30, 2025 | 5.08 Mn |
| Jun 30, 2025 | 5.08 Mn |
| Mar 31, 2025 | 4.88 Mn |
| Mar 31, 2025 | 4.88 Mn |
| Dec 31, 2024 | 13.94 Mn |
| Dec 31, 2024 | 13.94 Mn |
| Sep 30, 2024 | 9.00 Mn |
| Sep 30, 2024 | 9.00 Mn |
| Jun 30, 2024 | 683,000.00 |
| Jun 30, 2024 | 683,000.00 |
| Mar 31, 2024 | 100,000.00 |
| Mar 31, 2024 | 100,000.00 |